Literature DB >> 29614678

Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults.

William Charles Kreisl1, Peng Jin2, Seonjoo Lee2, Ezra R Dayan1, Shankar Vallabhajosula3, Gregory Pelton4, José A Luchsinger5, Gnanavalli Pradhaban4, D P Devanand4.   

Abstract

BACKGROUND: Odor identification deficits occur in Alzheimer's disease (AD), as measured by the 40-item University of Pennsylvania Smell Identification Test (UPSIT).
OBJECTIVE: To determine if UPSIT scores predict amyloid-β (Aβ) status, determined by 11C-Pittsburgh Compound B PET. We also compared UPSIT scores to Aβ status in predicting future memory decline.
METHODS: Subjects were recruited into a longitudinal clinical prediction study. We analyzed data from those who had UPSIT, cognitive testing, PIB PET, and at least 12 months' clinical follow-up. Forty-six amnestic mild cognitive impairment patients and 25 cognitively normal controls were included. Amyloid-positivity was defined as composite PIB standardized uptake value ratio >1.5. Logistic regression and Receiver Operating Characteristic Curve analyses tested the predictive utility of impaired olfaction (defined as UPSIT score <35) and amyloid-positivity for memory decline.
RESULTS: High UPSIT scores predicted absence of amyloidosis on PET, with negative predictive value of 100%. Positive predictive value of low UPSIT scores on positive Aβ status was only 41%. Both low UPSIT score (OR = 4.301, 95% CI = 1.248, 14.821, p = 0.021) and positive PET scan (OR = 20.898, 95% CI = 2.222, 196.581, p = 0.008) predicted memory decline.
CONCLUSION: Individuals with high UPSIT scores are less likely to have cerebral amyloidosis or experience memory decline. Therefore, UPSIT has potential as a screening tool to determine utility of Aβ PET in clinical practice or enrollment in clinical trials. Low UPSIT score is a non-specific marker of neurodegeneration that could indicate further workup in patients with memory complaints.

Entities:  

Keywords:  Alzheimer’s disease; amyloid; olfactory perception; positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 29614678      PMCID: PMC6760657          DOI: 10.3233/JAD-170960

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

Review 1.  Olfactory system: functional organization and involvement in neurodegenerative disease.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

2.  Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment.

Authors:  Nicola Canessa; Vincenza Castronovo; Stefano F Cappa; Mark S Aloia; Sara Marelli; Andrea Falini; Federica Alemanno; Luigi Ferini-Strambi
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

3.  The relationship between cerebral Alzheimer's disease pathology and odour identification in old age.

Authors:  R S Wilson; S E Arnold; J A Schneider; Y Tang; D A Bennett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-29       Impact factor: 10.154

4.  Pathologic changes in the olfactory system in aging and Alzheimer's disease.

Authors:  B T Hyman; P V Arriagada; G W Van Hoesen
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

5.  Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michelle M Mielke; H Randall Griffith; Abhay R Moghekar; Richard J O'Brien; Leslie M Shaw; John Q Trojanowski; Marilyn S Albert
Journal:  Arch Neurol       Date:  2011-01

6.  Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study.

Authors:  Alex Bahar-Fuchs; Gael Chételat; Victor L Villemagne; Simon Moss; Kerryn Pike; Colin L Masters; Christopher Rowe; Greg Savage
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

8.  Amyloid imaging in mild cognitive impairment subtypes.

Authors:  David A Wolk; Julie C Price; Judy A Saxton; Beth E Snitz; Jeffrey A James; Oscar L Lopez; Howard J Aizenstein; Ann D Cohen; Lisa A Weissfeld; Chester A Mathis; William E Klunk; Steven T De-Kosky; Steven T DeKoskym
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

9.  Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Authors:  A Okello; J Koivunen; P Edison; H A Archer; F E Turkheimer; K Någren; R Bullock; Z Walker; A Kennedy; N C Fox; M N Rossor; J O Rinne; D J Brooks
Journal:  Neurology       Date:  2009-07-08       Impact factor: 9.910

10.  Olfactory identification deficits and MCI in a multi-ethnic elderly community sample.

Authors:  D P Devanand; Matthias H Tabert; Katrina Cuasay; Jennifer J Manly; Nicole Schupf; Adam M Brickman; Howard Andrews; Truman R Brown; Charles DeCarli; Richard Mayeux
Journal:  Neurobiol Aging       Date:  2008-10-28       Impact factor: 4.673

View more
  9 in total

1.  Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4.

Authors:  Gonzalo Sánchez-Benavides; Gemma Salvadó; Eider M Arenaza-Urquijo; Oriol Grau-Rivera; Marc Suárez-Calvet; Marta Milà-Alomà; José María González-de-Echávarri; Carolina Minguillon; Marta Crous-Bou; Aida Niñerola-Baizán; Andrés Perissinotti; Juan Domingo Gispert; José Luis Molinuevo
Journal:  Alzheimers Dement (Amst)       Date:  2020-11-11

Review 2.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

3.  Intact global cognitive and olfactory ability predicts lack of transition to dementia.

Authors:  Davangere P Devanand; Seonjoo Lee; Jose A Luchsinger; Howard Andrews; Terry Goldberg; Edward D Huey; Nicole Schupf; Jennifer Manly; Yaakov Stern; William C Kreisl; Richard Mayeux
Journal:  Alzheimers Dement       Date:  2020-01-04       Impact factor: 21.566

4.  The utility of olfactory function in distinguishing early-stage Alzheimer's disease from HIV-associated neurocognitive disorders.

Authors:  Erin E Sundermann; Adam Fields; Rowan Saloner; Ben Gouaux; Ajay Bharti; Claire Murphy; David J Moore
Journal:  AIDS       Date:  2021-03-01       Impact factor: 4.632

5.  Olfactory testing does not predict β-amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort.

Authors:  Sarah M Buchanan; Thomas D Parker; Christopher A Lane; Ashvini Keshavan; Sarah E Keuss; Kirsty Lu; Sarah-Naomi James; Heidi Murray-Smith; Andrew Wong; Jennifer Nicholas; David M Cash; Ian B Malone; William Coath; David L Thomas; Carole Sudre; Nick C Fox; Marcus Richards; Jonathan M Schott
Journal:  J Neurol       Date:  2020-06-24       Impact factor: 4.849

6.  Effect of A/T/N imaging biomarkers on impaired odor identification in Alzheimer's disease.

Authors:  Min Seok Baek; Hanna Cho; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Chul Hyoung Lyoo
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

Review 7.  Could Early Identification of Changes in Olfactory Function Be an Indicator of Preclinical Neurodegenerative Disease? A Systematic Review.

Authors:  Rikki L Winchester; Kathy Martyn
Journal:  Neurol Ther       Date:  2020-06-11

8.  Association of Odor Identification Ability With Amyloid-β and Tau Burden: A Systematic Review and Meta-Analysis.

Authors:  Lihui Tu; Xiaozhen Lv; Zili Fan; Ming Zhang; Huali Wang; Xin Yu
Journal:  Front Neurosci       Date:  2020-11-26       Impact factor: 4.677

9.  Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium.

Authors:  Gabriel A de Erausquin; Heather Snyder; Traolach S Brugha; Sudha Seshadri; Maria Carrillo; Rajesh Sagar; Yueqin Huang; Charles Newton; Carmela Tartaglia; Charlotte Teunissen; Krister Håkanson; Rufus Akinyemi; Kameshwar Prasad; Giovanni D'Avossa; Gabriela Gonzalez-Aleman; Akram Hosseini; George D Vavougios; Perminder Sachdev; John Bankart; Niels Peter Ole Mors; Richard Lipton; Mindy Katz; Peter T Fox; Mohammad Zia Katshu; M Sriram Iyengar; Galit Weinstein; Hamid R Sohrabi; Rachel Jenkins; Dan J Stein; Jacques Hugon; Venetsanos Mavreas; John Blangero; Carlos Cruchaga; Murali Krishna; Ovais Wadoo; Rodrigo Becerra; Igor Zwir; William T Longstreth; Golo Kroenenberg; Paul Edison; Elizabeta Mukaetova-Ladinska; Ekkehart Staufenberg; Mariana Figueredo-Aguiar; Agustín Yécora; Fabiana Vaca; Hernan P Zamponi; Vincenzina Lo Re; Abdul Majid; Jonas Sundarakumar; Hector M Gonzalez; Mirjam I Geerlings; Ingmar Skoog; Alberto Salmoiraghi; Filippo Martinelli Boneschi; Vibuthi N Patel; Juan M Santos; Guillermo Rivera Arroyo; Antonio Caballero Moreno; Pascal Felix; Carla Gallo; Hidenori Arai; Masahito Yamada; Takeshi Iwatsubo; Malveeka Sharma; Nandini Chakraborty; Catterina Ferreccio; Dickens Akena; Carol Brayne; Gladys Maestre; Sarah Williams Blangero; Luis I Brusco; Prabha Siddarth; Timothy M Hughes; Alfredo Ramírez Zuñiga; Joseph Kambeitz; Agustin Ruiz Laza; Norrina Allen; Stella Panos; David Merrill; Agustín Ibáñez; Debby Tsuang; Nino Valishvili; Srishti Shrestha; Sophia Wang; Vasantha Padma; Kaarin J Anstey; Vijayalakshmi Ravindrdanath; Kaj Blennow; Paul Mullins; Emilia Łojek; Anand Pria; Thomas H Mosley; Penny Gowland; Timothy D Girard; Richard Bowtell; Farhaan S Vahidy
Journal:  Alzheimers Dement (N Y)       Date:  2022-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.